Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation

By: via Benzinga
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.